EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
EKF Diagnostics announces that Ron Zwanziger has been appointed as Non-Executive Chairman with immediate effect.
EKF Diagnostics, the global in vitro diagnostics company, announces that it will launch the Altair™ 240 clinical chemistry analyzer to the European market at Medica 2015, Düsseldorf, 16-19th November.
Data presented for sTNFR1 at ASN, San Diego.
The Company has entered into an agreement with the majority of the former shareholders of Selah Genomics Inc.
Data presented for sTNFR1 at ASN, San Diego.
The Board note the announcement by Jinjing (Group) Co., Ltd. that they do not intend to make an offer for the Company.
The Board note the announcement by Jinjing (Group) Co., Ltd. that they do not intend to make an offer for the Company.
The deadline for Jinjing has been extended to 5pm on 19 October 2015.
Newsletter
Keep up to date with all our activities, events, exhibitions, promotions, investor news & more.